RESEARCH

Systolic Blood Pressure Intervention Trial (SPRINT)

Blood Pressure and Kidney Function - SPRINT vs Electronic Health Record Data 

Principal Investigator
Paul Drawz, MD

Program Manager
Nayanjot Kaur Rai, MPH, BDS
rai00041@umn.edu

Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

CLINICAL TRIAL

---

Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)

Principal Investigator
Paul Drawz, MD

Program Manager
Nayanjot Kaur Rai, MPH, BDS
rai00041@umn.edu

Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu 

CLINICAL TRIAL

More Coming Soon

More Coming Soon

Phase 3 Trial
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Principal Investigator
Michelle Rheault, MD

Study Coordinator
Amy Hanson, CCRC
amhanson@umn.edu

CLINICAL TRIAL

Phase 3 Trial

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)

Principal Investigator
Surabhi Thakar, MD

Co-Investigator
Katti Woerner, MD

Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

---

Phase 3 Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

Principal Investigator
Patrick H. Nachman, MD

Study Coordinators
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

Systolic Blood Pressure Intervention Trial (SPRINT)\

Principal Investigator
Paul Drawz, MD

Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

CLINICAL TRIAL

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Principal Investigator
Samy Riad, MD, MS

Co-Investigator
Richard Spong, MD

Study Coordinator
Ghislaine Feussom
feuss001@umn.edu

CLINICAL TRIAL 

---

Phase 3

A Randomized, Controlled, Multi-Center, Safety and Efficacy Study of FCR001 Cell-Based Therapy Relative to a Tacrolimus and Mycophenolate-Based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)

Principal Investigator
Erik Finger, MD, PhD

Co-Investigator
Samy Riad, MD, MS

Study Coordinator
Dave Ankarlo
anka0004@umn.edu

CLINICAL TRIAL 

---

Immunosuppression Reduction in Failed Allograft Guided by cfDNA

Principal Investigator
Samy Riad, MD, MS

Study Coordinator
Ghislaine Feussom
feuss001@umn.edu

CLINICAL TRIAL

---

Cf-DNA Assay During Treatment of Acute Rejection-Pilot Study

Principal Investigator
Arthur Matas, MD

Co-Investigators
Samy Riad, MD, MS

Adam Bregman, MD, MBA

Study Coordinators
Marcia Brott
brott001@umn.edu

Amanda Contreras
contr014@umn.edu

CLINICAL TRIAL

---

Phase 1 and Phase 2 Trial

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Principal Investigator
Michelle Rheault, MD

Co-Investigator
Samy Riad, MD, MS

Study Coordinators
Marcia Brott
brott001@umn.edu

Thu Danh, MPH
danhx005@umn.edu

CLINICAL TRIAL

Phase 2 Trial

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)

Principal Investigator
Patrick Nachman, MD

Study Coordinators

Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

The Nephrotic Syndrome Study Network (NEPTUNE)

Principal Investigator
Patrick Nachman, MD

Co-Principal Investigator
Michelle Rheault, MD

Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

Phase 2 Trial

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus 

Principal Investigator
Dr. Parastoo Fazeli

Study Coordinator
Julie Scherber
sche0245@umn.edu

CLINICAL TRIAL

---

Phase 3 Trial

A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Surabhi Thakar, MD 

Parastoo Fazeli, MD

Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu

CLINICAL TRIAL

---

Phase 3 Trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

Principal Investigator
Surabhi Thakar, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL